"目錄號(hào): HY-13618
Edotecarin 是一種有效的topoisomerase I抑制劑贼邓，可誘導(dǎo)單鏈 DNA 斷裂曙蒸，IC50值為 50 nM。
相關(guān)產(chǎn)品
Doxorubicin hydrochloride-Etoposide-INNO-206-Irinotecan hydrochloride-Campathecin-Daunorubicin Hydrochloride-Topotecan Hydrochloride-Epirubicin hydrochloride-Exatecan Mesylate-SN-38-Idarubicin hydrochloride-Daun02-Tirapazamine-Amsacrine-TAS-103 dihydrochloride-
生物活性
Description
Edotecarin is a potent inhibitor oftopoisomerase Ithat can induces single-strand DNA cleavage, withIC50of 50 nM.
IC50& Target
IC50: 50 nM (topoisomerase I)[1]
In Vitro
In the presence of human colon cancer cells labeled with3Hthymidine, edotecarin (0.6 μmol/L) increases the formation of DNA-protein complexes in a time-dependent manner[1].
In Vivo
Edotecarin produces an 83% increase in survival in mice bearing intracranial D-456MG glioma and shows a strong antimetastatic effect[1]. Edotecarin results in tumor growth delays ranging from 10.45 days at the lowest dose (3 mg/kg) to 24.83 days at the highest (100 mg/kg). Combination treatment of edotecarin plus irinotecan improves antitumor activity in vivo compared with either agent alone[2].
Clinical Trial
Pfizer
Stomach Neoplasms
April 2004
Phase 2
Pfizer
Glioblastoma
August 2003
Phase 3
Memorial Sloan Kettering Cancer Center-National Cancer Institute (NCI)
Breast Cancer
June 2003
Phase 2
Memorial Sloan Kettering Cancer Center-National Cancer Institute (NCI)
Esophageal Cancer-Gastric Cancer-Unspecified Adult Solid Tumor, Protocol Specific
August 2003
Phase 1
Pfizer
Breast Neoplasms-Neoplasm Metastasis
June 2003
Phase 2
View MoreCollapse
References
